"From late 2020 to the summer of 2024, Eli Lilly & Co. ( NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather this year. The past couple of years have been a transformative time for the Indianapolis-based pharmaceutical giant, with substantial financial growth driven by its innovative medicines and GLP-1 drugs, significant regulatory successes, and continued investment in its pipeline and manufacturing capabilities. Meanwhile, it has struggled to meet overwhelming demand and faces intense competition in the weight-loss space."
"Now, the share price is 34.6% higher than six months ago, including an 18.6% run in the past month, when Lilly struck a deal with the U.S. government to significantly lower prices on GLP-1 products in exchange for expanded access and coverage within federal programs. It also posted positive clinical trial results and robust third-quarter earnings in that time, and it finalized its acquisition of Adverum Biotechnologies and announced a partnership with AI chipmaker Nvidia Corp. ( NASDAQ: NVDA)."
Eli Lilly experienced dramatic share-price appreciation from late 2020 through mid-2024, driven primarily by successful GLP-1 weight-loss drugs, regulatory approvals, and investments in R&D and manufacturing. Revenue rose about 60% since 2016 while net income increased roughly 91%, and recent quarters included positive clinical results and strong third-quarter earnings. Recent actions include a U.S. government agreement to lower GLP-1 prices in exchange for broader federal program access, completion of the Adverum Biotechnologies acquisition, and a partnership with Nvidia. Continued demand-supply challenges, intense competition in the weight-loss market, and future revenue and net-income trajectories will influence stock performance through 2025–2030.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]